CRANFORD, N.J., Sept. 13,
2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
("Citius" or the "Company") (Nasdaq: CTXR) mourns the loss of
longtime board member, Howard Safir,
who passed away on Monday. Mr. Safir joined the Citius Board of
Directors in 2014, providing invaluable counsel to the Citius
management team for nearly a decade.
"We are deeply saddened to announce the passing of our friend
and longtime board member, Howard
Safir. Howard was an outstanding and admirable leader whose
insights helped shape the growth of Citius for almost ten years. We
are honored to have worked alongside Howard on the Citius board and
grateful for his thoughtful guidance, wisdom, and friendship," said
Leonard Mazur, Chairman and Chief
Executive Officer of Citius Pharmaceuticals. "On behalf of our
entire organization and Board of Directors, we wish to extend our
deepest condolences and sympathies to Howard's family and friends.
May his legacy be an enduring commitment to positively impacting
society."
Throughout his distinguished career, Howard Safir's dedication to public service was
an inspiration to many. Prior to joining the Citius Board of
Directors in 2014, Howard served as Chairman and Chief Executive
Officer multiple security consulting firms following his tenures as
the 39th Police Commissioner of the City
of New York, Associate Director for Operations of the US
Marshals Service, and Assistant Director of the Drug Enforcement
Administration. In addition to his role as the Lead Independent
Director at Citius, he served on the boards of several life
science and technology companies. He will be greatly missed by the
Citius family.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to
the development and commercialization of first-in-class critical
care products, with a focus on oncology, anti-infectives in adjunct
cancer care, unique prescription products, and stem cell therapies.
The Company's diversified pipeline includes two late-stage product
candidates, Mino-Lok®, an antibiotic lock solution for
the treatment of patients with catheter-related bloodstream
infections, which is currently enrolling patients in a Phase 3
Pivotal superiority trial, and LYMPHIR™, a novel IL-2R
immunotherapy for an initial indication in CTCL. Mino-Lok was
granted Fast Track designation by the FDA. LYMPHIR received orphan
drug designation by the FDA for the treatment of CTCL and PTCL. At
the end of March 2023, Citius
completed enrollment in its Phase 2b
trial of CITI-002, a topical formulation for the relief of
hemorrhoids. For more information, please
visit www.citiuspharma.com.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-mourns-the-loss-of-board-member-howard-safir-301926915.html
SOURCE Citius Pharmaceuticals, Inc.